Poll

Expanded Medicare Coverage of Continuous Glucose Monitors

Rachel Stahl Salzman, MS, RDN, CDN, CDCES

This poll question is based on an episode of Nutrition411:The Podcast, “Smart Solutions for Diabetes Care: Combining Nutrition, Dietitians, and Technology.”

Listen to the full podcast here.

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.

Current Consultant Issue

Previous Issues

Early View

Research Summaries

Conference Coverage

Dextromethorphan-Bupropion Delays Relapse of Agitation Symptoms in Patients Diagnosed With Probable Alzheimer Disease

04/29/2024

Anthony Calabro, MA

Researchers evaluated the safety and efficacy of dextromethorphan-bupropion, an FDA approved treatment of major depression disorder, for Alzheimer disease-related agitation. This study was presented at the...

04/29/2024

Research Summary

Heart Rate Variability Associated With Increased Risk of Agitation Among Patients With Alzheimer Disease

04/24/2024

Anthony Calabro, MA

Researchers collected data from the Atherosclerosis Risk in Communities Study to determine whether heart rate variability was associated with agitation risk in individuals clinically diagnosed with dementia...

04/24/2024

FDA Alert

FDA Grants Accelerated Approval for First CAR-T Cell Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

04/22/2024

Anthony Calabro, MA

The FDA previously approved lisocabtagene maraleucel as a second-line treatment option for adult patients with large B-cell lymphoma in June 2022.

04/22/2024

research summary

research summary

Monthly Treatment Is Safe, Efficacious for Acute Hepatic Porphyria

04/19/2024

Individuals with acute hepatic porphyria often experience acute attacks and chronic symptoms which greatly diminish their quality of life. Researchers examined the efficacy of givosiran in reducing these...

04/19/2024

FDA Alert

FDA Approves First Nonsteroidal Treatment for Patients With Duchenne Muscular Dystrophy

04/18/2024

Anthony Calabro, MA

The FDA approved givinostat, a nonsteroidal oral medication, for treating patients 6 years of age or older with Duchenne muscular dystrophy.

04/18/2024

Trending Articles

Photo Quiz

Recurrent Pruritic Erythematous and Pigmented Plaques

04/26/2024

Thomas N. Helm, MD¹ • Allison Tobias, BS² • Sarah Albert² • Robert E. Kalb, MD²

Thomas N. Helm, MD1 • Allison Tobias, BS2 • Sarah Albert 2 • Robert E. Kalb, MD2 ...

04/26/2024

pop quiz

Diagnosing Herpes Zoster

04/18/2024

Photo Essay

An Atlas of Lumps and Bumps, Part 37: Keratosis Pilaris

04/15/2024

Alexander K.C. Leung, MD^1,2, Benjamin Barankin, MD³, Joseph M. Lam, MD⁴, Kin Fon Leong, MD⁵

Alexander K.C. Leung, MD1,2, Benjamin Barankin, MD3, Joseph M. Lam, MD4, Kin Fon Leong,...

Keratosis Pilaris Keratosis pilaris, frequently referred to as “chicken skin” by patients, is a disorder of keratinization of the infundibulum of pilosebaceous follicles characterized by keratinous plugs...

04/15/2024

poll

Multivitamin Supplementation for Cognitive Function

04/16/2024

Multiple studies have shown the benefit of daily multivitamin use on older adults’ memory, cognitive function, and cognitive aging. How often do you discuss multivitamin supplementation with your...

04/16/2024

Video

No Difference Between Hypotension-Avoidance and Hypertension-Avoidance Strategies for Reducing Post-Surgical Adverse Events

04/11/2024

In this video, Maura Marcucci, MD, MSc, discusses her study's surprising results, which showed no differences between hypotension-avoidance and hypertension-avoidance strategies for decreasing adverse...

04/11/2024

Expanded Medicare Coverage of Continuous Glucose Monitors

© 2023 HMP Global. All Rights Reserved.Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.